Description: CEL-SCI Corporation engages in the research and development of drugs and vaccines. The company's principal product, Multikine, is under Phase III clinical trial for the treatment of head and neck cancer. The Multikine is an immunotherapeutic agent consisting of a mixture of cytokines that produce an anti-tumor immune response. It also develops Ligand Epitope Antigen Presentation System (LEAPs), a heteroconjugate technology that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune, allergies, transplantation rejection, and cancer. The company, through its LEAPS technology, develops a peptide treatment for H1N1 hospitalized patients; and CEL-2000, a rheumatoid arthritis vaccine. CEL-SCI Corporation was founded in 1983 and is based in Vienna, Virginia.
Home Page: cel-sci.com
CVM Technical Analysis
8229 Boone Boulevard
Vienna,
VA
22182
United States
Phone:
703 506 9460
Officers
| Name | Title |
|---|---|
| Mr. Geert R. Kersten Esq. | Chief Exec. & Financial Officer, Treasurer and Director |
| Ms. Patricia B. Prichep | Sr. VP of Operations & Corp. Sec. |
| Dr. Eyal Talor Ph.D. | Chief Scientific Officer |
| Dr. Daniel H. Zimmerman Ph.D. | Sr. VP of Research & Cellular Immunology |
| Mr. John Cipriano | Sr. VP of Regulatory Affairs |
Exchange: NYSE MKT
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.6763 |
| Price-to-Sales TTM: | 11797.424 |
| IPO Date: | 1987-01-01 |
| Fiscal Year End: | September |
| Full Time Employees: | 0 |